05.01.2022 - Press Release Stockholm, Sweden, January 5, 2022 Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors .
Press Release Stockholm, Sweden, January 3, 2022 Immunicum to Participate in Upcoming Investor and Industry Conferences in January Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical
21.12.2021 - Press Release Stockholm, Sweden, December 21, 2021 Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical .
Press ReleaseStockholm, Sweden, November 22, 2021Immunicum Publishes DCP-001 Mechanism of Action in the Journal CellsImmunicum ABas part of the Special Issue Allogeneic Cell Cancer Immunotherapies.About